## Glenmark Pharmaceuticals Limited (GLENMARK) Stock Analysis

This report analyzes the provided data for Glenmark Pharmaceuticals Limited (GLENMARK) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                               |
|-----------------|------------------------------------|
| Symbol           | GLENMARK                           |
| Company Name     | Glenmark Pharmaceuticals Limited    |
| Industry         | Pharmaceuticals                     |
| ISIN             | INE935A01035                        |
| Listing Date     | 2000-02-07                          |


**1.2 Market Data:**

| Metric                | Value     |
|-----------------------|------------|
| Last Price            | 1,545.00   |
| Change                | 4.20       |
| % Change              | 0.27%      |
| Previous Close        | 1,540.80   |
| Open                  | 1,530.05   |
| Close                 | 1,541.65   |
| VWAP                  | 1,546.06   |
| Week High             | 1,830.95   |
| Week Low              | 771.00     |
| Sector PE             | 0          |
| Symbol PE             | 0          |
| Delivery to Traded % | 50.55%     |
| Daily Volatility      | 1.92%      |
| Annual Volatility     | 36.68%     |


**1.3 Pre-Open Market Data:**

The pre-open market showed limited activity with a final price of 1,530.05, lower than the previous close.  Buy orders were significantly lower than sell orders.

**1.4 Corporate Actions:**

| Ex-Date       | Purpose                               |
|---------------|---------------------------------------|
| 13-Sep-2024   | Dividend - Rs 2.50 Per Share          |
| 18-Sep-2023   | Dividend - Rs 2.50 Per Share          |
| 12-Sep-2022   | Annual General Meeting/Dividend - Rs 2.50 Per Share |
| ...           | ... (Further historical dividend data available) |


**1.5 Recent Announcements:**

* 18-Dec-2024: Acquisition (XBRL and non-XBRL announcements)
* 16-Dec-2024: Press Release
* 10-Dec-2024: Press Release
* ... (Further announcements available)


**1.6 Financial Results (Last Five Quarters):**

| Quarter End      | Income       | Expenditure  | Profit After Tax | Diluted EPS |
|-----------------|--------------|---------------|-------------------|-------------|
| 30-Sep-2024     | 271,917.6    | 192,411.7     | 59,505.6         | 21.09       |
| 30-Jun-2024     | 238,518.5    | 176,687.1     | 45,373.1         | 16.08       |
| 31-Mar-2024     | 293,449.3    | 178,656.1     | 461,369.5        | 163.5       |
| 31-Dec-2023     | 162,391.1    | 167,413       | -2,040.9         | -0.72       |
| 30-Sep-2023     | 227,963.3    | 187,059.8     | 30,235.4         | 10.72       |


**1.7 Shareholding Patterns:**

Promoter holding has remained relatively stable around 46.65% over the last four quarters.  No significant changes are observed.


**1.8 Key Directors and Contact Information:**

(Data available in the provided JSON, but omitted here for brevity.  This information is readily accessible from the structured data.)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (1,545.00) is slightly higher than the previous close (1,540.80) and the pre-open price (1,530.05).
* It's significantly below the week high (1,830.95) and above the week low (771.00).

**2.2 Financial Performance:**

* Revenue shows some fluctuation but generally positive growth over the last five quarters.
* Profitability is inconsistent, with significant profit in Q1 2024 and losses in Q4 2023.
* EPS is highly volatile, indicating significant risk.  The exceptionally high EPS in Q1 2024 needs further investigation to understand the underlying reasons.

**2.3 Shareholding Analysis:**

* Promoter holding is stable, suggesting no major internal changes affecting the company's direction.

**2.4 Corporate Action Summary:**

* Consistent dividend payments over several years.  The recent dividend of Rs 2.50 per share is positive.

**2.5 Volatility and Risk:**

* High daily (1.92%) and annual (36.68%) volatility indicates significant risk.  The inconsistent profitability further supports this.

**3. Final Verdict:**

**Don't Buy.**

**Reasoning:** While the company shows some positive signs like consistent dividend payments and generally increasing revenue, the significant volatility, inconsistent profitability (including a substantial loss in Q4 2023), and the exceptionally high EPS in Q1 2024 (requiring further investigation) raise serious concerns.  The high volatility suggests a high-risk investment, which is not justified by the current data.  Further investigation into the reasons behind the Q1 2024 EPS surge is crucial before considering any investment.

**Conclusion:** Based on the provided financial data and market indicators, Glenmark Pharmaceuticals presents a high-risk profile with inconsistent performance.  The lack of transparency regarding the Q1 2024 EPS spike necessitates further due diligence before any investment decision.  A "Don't Buy" recommendation is given until more information is available to clarify the financial inconsistencies.
